Drugs Made In America Acquisition Corp. Files S-1/A Amendment

TL;DR

DMAA files S-1/A amendment, more details coming soon.

AI Summary

Drugs Made In America Acquisition Corp. filed an S-1/A amendment on November 25, 2024, for its registration statement. The company, incorporated in the Cayman Islands, is a blank check company (SIC code 6770) and is amending its filing related to its securities. The principal executive offices are located at 2 Pelican Dr., Fort Lauderdale, FL 33301.

Why It Matters

This S-1/A filing indicates ongoing regulatory activity and potential future public offerings or business combinations for Drugs Made In America Acquisition Corp.

Risk Assessment

Risk Level: medium — As a blank check company (SPAC), its success is highly dependent on identifying and completing a suitable acquisition, which carries inherent risks.

Key Numbers

• 333-281170 — SEC File Number (Identifies the specific registration filing with the SEC.)
• 6770 — SIC Code (Classifies the company as a 'Blank Checks' entity, indicating its nature as a SPAC.)

Key Players & Entities

• Drugs Made In America Acquisition Corp. (company) — Registrant
• November 25, 2024 (date) — Filing date
• Cayman Islands (location) — Jurisdiction of incorporation
• 6770 (number) — Standard Industrial Classification (SIC) code for Blank Checks
• 333-281170 (number) — SEC File Number
• 2 Pelican Dr., Fort Lauderdale, FL 33301 (address) — Principal executive offices
• Lynn Stockwell (person) — Executive Chair

FAQ

Key Financial Figures

• $200,000,000 — ER 25 , 2024 PRELIMINARY PROSPECTUS $200,000,000 Drugs Made In America Acquisition Cor
• $10.00 — ies. Each unit has an offering price of $10.00 and consists of one ordinary share and
• $0.10 — onsor depositing into the trust account $0.10 per public share outstanding in
• $100,000 — awn to pay our taxes, if any, and up to $100,000 of interest to pay dissolution expenses
• $4,000,000 — ) at a price of $10.00 per unit ($4,000,000 in the aggregate, or $4,300,000 in the
• $4,300,000 — r unit ($4,000,000 in the aggregate, or $4,300,000 in the aggregate if the underwriters&#x
• $35,000 — dinary shares (which were purchased for $35,000 and which we refer to as “founde
• $0.05 — #x00a0;     $0.05 per unit sold in the base offering, or
• $1,000,000 — the gross proceeds of the offering, or $1,000,000 (or up to $1,150,000 if the overallotme
• $1,150,000 — f the offering, or $1,000,000 (or up to $1,150,000 if the overallotment option is exercise
• $0.30 — the closing of this offering. Includes $0.30 per unit, or 3.0% of the gross proceeds
• $6,000,000 — the gross proceeds of the offering, or $6,000,000 (or up to $6,900,000 if the underwriter
• $6,900,000 — f the offering, or $6,000,000 (or up to $6,900,000 if the underwriters’ over -allot
• $201.0 m — ate units described in this prospectus, $201.0 million, or $231.15 million if the underw
• $231.15 million — in this prospectus, $201.0 million, or $231.15 million if the underwriters’ over -allot

Filing Documents

• ea0209546-07.htm (S-1/A) — 4471KB
• ea020954607ex1-1_drugs.htm (EX-1.1) — 236KB
• ea020954607ex10-9_drugs.htm (EX-10.9) — 10KB
• ea020954607ex23-1_drugs.htm (EX-23.1) — 2KB
• 0001213900-24-102238.txt ( ) — 4721KB

Risk factors

Risk factors   34 Cautionary note regarding forward-looking statements   73

Use of proceeds

Use of proceeds   75 Dividend policy   79

Dilution

Dilution   80 Capitalization   83 Management’s discussion and analysis of financial condition and resul ts of operations   84 Proposed business   89 Management   113 Principal shareholders   121 Certain relationships and related party transactions   124

Description of securities

Description of securities   127 MATERIAL United states federal income tax considerations   142

Underwriting

Underwriting   151 Legal matters   159 Experts   159 Where you can find additional information   159 Index to Financial Statements   F-1 This prospectus contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. i Table of Contents Summary This summary only highlights the more detailed information appearing elsewhere in this prospectus. As this is a summary, it does not contain all of the information that you should consider in making an investment decision. You should read this entire prospectus carefully, including the information under “Risk Factors” and our financial statements and the related notes included elsewhere in this prospectus, before investing. General Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses, which we refer to throughout this prospectus as our “initial business combination.” To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive disc

View Full Filing

View this S-1/A filing on SEC EDGAR